Discovery
The Grohar lab uses a variety of unbiased screening approaches to identify active compounds and combinations both in our lab and in collaboration with other investigators and biotechnology companies. These studies involve FDA approved compounds as well as novel compounds. More recently, we have focused on the identification of molecular targets that perturb the activity of EWS::FLI1 as a means to better understand the biology of target inhibition and to identify new agents.